ConforMIS, Inc., a medical technology company, develops, manufactures, and sells customized joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee, as well as provides iJigs, customized single-use patient-specific instruments. It is also developing iTotal Hip, a customized total hip replacement implant. The company markets and sells its products through direct sales...
28 Crosby Drive
Bedford, MA 01730
Founded in 2004
ConforMis, Inc. Reports Un-Audited Consolidated Earnings Results for the First Quarter Ended March 31, 2016; Provides Earnings Guidance for the Second Quarter and Full Year of 2016
May 12 16
ConforMIS, Inc. reported un-audited consolidated earnings results for the first quarter ended March 31, 2016. For the quarter, the company reported total revenue of $20,250,000 compared to $14,700,000 a year ago. Loss from operations was $15,144,000 compared with $14,063,000 a year ago. Net loss was $15,034,000 compared with $14,257,000 a year ago. Basic and Diluted loss per share were $0.37 compared with $3.32 a year ago. Loss before income taxes was $15,030,000 compared with $14,247,000 a year ago.
For the second quarter, the company expects total revenue in a range of $17.7 million to $18.7 million and product revenue in a range of $17.5 million to $18.5 million, representing year-over-year product revenue growth of 11% to 17% on a reported basis and a constant currency basis.
For the full year of 2016, the company expects total revenue in a range of $76 million to $81 million, from previous guidance in a range of $84 million to $87 million. Product revenue in a range of $75 million to $80 million, representing year-over-year growth of 19% to 27% on a reported basis and 20% to 28% on a constant currency basis. This is updated from previous guidance in a range of $83 million to $86 million, representing year-over-year growth of 32% to 37% on a reported basis and 33% to 38% on a constant currency basis. Royalty revenue guidance of approximately $0.8 million related to ongoing patent license royalty payments has not changed.
ConforMIS, Inc. Announces Departure of Philipp Lang as President Chief Executive Officer
May 12 16
ConforMIS, Inc. Board of Directors has retained an executive search firm to search for a new President and Chief Executive Officer to succeed Dr. Philipp Lang. The company expects that Dr. Lang will remain the CEO until the successor has been appointed and Dr. Lang will continue to serve on the Board of Directors.
ConforMIS, Inc. to Report Q1, 2016 Results on May 12, 2016
Apr 21 16
ConforMIS, Inc. announced that they will report Q1, 2016 results at 9:05 PM, GMT Standard Time on May 12, 2016